GSTM1 genotype is an independent prognostic factor in clear cell renal cell carcinoma
Owing to dual functionality of cytosolic glutathione S-transferases (GSTs), they might affect both the development and the progression of renal cell carcinoma (RCC). However, the data on the prognostic value of GST polymorphism in patients with RCC are scarce. Hence, we evaluated the effect of GST g...
Uloženo v:
| Vydáno v: | Urologic oncology Ročník 35; číslo 6; s. 409 - 417 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Elsevier Inc
01.06.2017
|
| Témata: | |
| ISSN: | 1078-1439, 1873-2496, 1873-2496 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Owing to dual functionality of cytosolic glutathione S-transferases (GSTs), they might affect both the development and the progression of renal cell carcinoma (RCC). However, the data on the prognostic value of GST polymorphism in patients with RCC are scarce. Hence, we evaluated the effect of GST gene variants on both the risk of RCC development and the postoperative prognosis in patients with clear cell RCC (ccRCC).
GST genotypes were determined in 305 patients with RCC and 326 matched controls, whereas the overall survival was evaluated in patients with ccRCC only. The presence of GSTM1:ASK1 protein-protein interaction in ccRCC tissue samples was analyzed by methods of immunoprecipitation and immunoblot.
We noted an increased risk of RCC development in carriers of GSTM1-null and GSTP1-variant genotype (P<0.05). On the contrary, survival analysis indicated shorter overall survival for patients with ccRCC with GSTM1-active genotype (P = 0.026). Furthermore, patients with ccRCC with GSTM1-active genotype had significantly higher hazard ratio (P<0.05), in analyzed regression models, compared with the carriers of GSTM1-null genotype. Finally, the presence of GSTM1:ASK1 protein-protein interaction was found in all RCC tissue samples studied.
Carriers of GSTM1-null and GSTP1-variant genotypes are in increased risk of RCC development. On the contrary, GSTM1-null genotype is associated with favorable postoperative prognosis in ccRCC. The possible molecular mechanism underlying the role of GSTM1 protein in RCC progression might be the presence of GSTM1:ASK1 protein-protein interaction. Hence, determination of GSTM1-genotype might serve as a valuable indicator in both RCC risk assessment and postoperative prognosis.
•Patients with clear cell RCC and GSTM1-null genotype have longer overall survival.•GSTM1-active genotype is an independent predictor of higher ccRCC mortality risk.•ASK1:GSTM1 interaction might be mechanism underlying GSTs’ prognostic role in ccRCC. |
|---|---|
| AbstractList | Owing to dual functionality of cytosolic glutathione S-transferases (GSTs), they might affect both the development and the progression of renal cell carcinoma (RCC). However, the data on the prognostic value of GST polymorphism in patients with RCC are scarce. Hence, we evaluated the effect of GST gene variants on both the risk of RCC development and the postoperative prognosis in patients with clear cell RCC (ccRCC).
GST genotypes were determined in 305 patients with RCC and 326 matched controls, whereas the overall survival was evaluated in patients with ccRCC only. The presence of GSTM1:ASK1 protein-protein interaction in ccRCC tissue samples was analyzed by methods of immunoprecipitation and immunoblot.
We noted an increased risk of RCC development in carriers of GSTM1-null and GSTP1-variant genotype (P<0.05). On the contrary, survival analysis indicated shorter overall survival for patients with ccRCC with GSTM1-active genotype (P = 0.026). Furthermore, patients with ccRCC with GSTM1-active genotype had significantly higher hazard ratio (P<0.05), in analyzed regression models, compared with the carriers of GSTM1-null genotype. Finally, the presence of GSTM1:ASK1 protein-protein interaction was found in all RCC tissue samples studied.
Carriers of GSTM1-null and GSTP1-variant genotypes are in increased risk of RCC development. On the contrary, GSTM1-null genotype is associated with favorable postoperative prognosis in ccRCC. The possible molecular mechanism underlying the role of GSTM1 protein in RCC progression might be the presence of GSTM1:ASK1 protein-protein interaction. Hence, determination of GSTM1-genotype might serve as a valuable indicator in both RCC risk assessment and postoperative prognosis.
•Patients with clear cell RCC and GSTM1-null genotype have longer overall survival.•GSTM1-active genotype is an independent predictor of higher ccRCC mortality risk.•ASK1:GSTM1 interaction might be mechanism underlying GSTs’ prognostic role in ccRCC. Owing to dual functionality of cytosolic glutathione S-transferases (GSTs), they might affect both the development and the progression of renal cell carcinoma (RCC). However, the data on the prognostic value of GST polymorphism in patients with RCC are scarce. Hence, we evaluated the effect of GST gene variants on both the risk of RCC development and the postoperative prognosis in patients with clear cell RCC (ccRCC). GST genotypes were determined in 305 patients with RCC and 326 matched controls, whereas the overall survival was evaluated in patients with ccRCC only. The presence of GSTM1:ASK1 protein-protein interaction in ccRCC tissue samples was analyzed by methods of immunoprecipitation and immunoblot. We noted an increased risk of RCC development in carriers of GSTM1-null and GSTP1-variant genotype (P<0.05). On the contrary, survival analysis indicated shorter overall survival for patients with ccRCC with GSTM1-active genotype (P = 0.026). Furthermore, patients with ccRCC with GSTM1-active genotype had significantly higher hazard ratio (P<0.05), in analyzed regression models, compared with the carriers of GSTM1-null genotype. Finally, the presence of GSTM1:ASK1 protein-protein interaction was found in all RCC tissue samples studied. Carriers of GSTM1-null and GSTP1-variant genotypes are in increased risk of RCC development. On the contrary, GSTM1-null genotype is associated with favorable postoperative prognosis in ccRCC. The possible molecular mechanism underlying the role of GSTM1 protein in RCC progression might be the presence of GSTM1:ASK1 protein-protein interaction. Hence, determination of GSTM1-genotype might serve as a valuable indicator in both RCC risk assessment and postoperative prognosis. Abstract Purpose Owing to dual functionality of cytosolic glutathione S-transferases (GSTs), they might affect both the development and the progression of renal cell carcinoma (RCC). However, the data on the prognostic value of GST polymorphism in patients with RCC are scarce. Hence, we evaluated the effect of GST gene variants on both the risk of RCC development and the postoperative prognosis in patients with clear cell RCC (ccRCC). Methods GST genotypes were determined in 305 patients with RCC and 326 matched controls, whereas the overall survival was evaluated in patients with ccRCC only. The presence of GSTM1:ASK1 protein-protein interaction in ccRCC tissue samples was analyzed by methods of immunoprecipitation and immunoblot. Results We noted an increased risk of RCC development in carriers of GSTM1-null and GSTP1-variant genotype ( P <0.05). On the contrary, survival analysis indicated shorter overall survival for patients with ccRCC with GSTM1-active genotype ( P = 0.026). Furthermore, patients with ccRCC with GSTM1-active genotype had significantly higher hazard ratio ( P <0.05), in analyzed regression models, compared with the carriers of GSTM1-null genotype. Finally, the presence of GSTM1:ASK1 protein-protein interaction was found in all RCC tissue samples studied. Conclusions Carriers of GSTM1-null and GSTP1-variant genotypes are in increased risk of RCC development. On the contrary, GSTM1-null genotype is associated with favorable postoperative prognosis in ccRCC. The possible molecular mechanism underlying the role of GSTM1 protein in RCC progression might be the presence of GSTM1:ASK1 protein-protein interaction. Hence, determination of GSTM1 -genotype might serve as a valuable indicator in both RCC risk assessment and postoperative prognosis. Owing to dual functionality of cytosolic glutathione S-transferases (GSTs), they might affect both the development and the progression of renal cell carcinoma (RCC). However, the data on the prognostic value of GST polymorphism in patients with RCC are scarce. Hence, we evaluated the effect of GST gene variants on both the risk of RCC development and the postoperative prognosis in patients with clear cell RCC (ccRCC).PURPOSEOwing to dual functionality of cytosolic glutathione S-transferases (GSTs), they might affect both the development and the progression of renal cell carcinoma (RCC). However, the data on the prognostic value of GST polymorphism in patients with RCC are scarce. Hence, we evaluated the effect of GST gene variants on both the risk of RCC development and the postoperative prognosis in patients with clear cell RCC (ccRCC).GST genotypes were determined in 305 patients with RCC and 326 matched controls, whereas the overall survival was evaluated in patients with ccRCC only. The presence of GSTM1:ASK1 protein-protein interaction in ccRCC tissue samples was analyzed by methods of immunoprecipitation and immunoblot.METHODSGST genotypes were determined in 305 patients with RCC and 326 matched controls, whereas the overall survival was evaluated in patients with ccRCC only. The presence of GSTM1:ASK1 protein-protein interaction in ccRCC tissue samples was analyzed by methods of immunoprecipitation and immunoblot.We noted an increased risk of RCC development in carriers of GSTM1-null and GSTP1-variant genotype (P<0.05). On the contrary, survival analysis indicated shorter overall survival for patients with ccRCC with GSTM1-active genotype (P = 0.026). Furthermore, patients with ccRCC with GSTM1-active genotype had significantly higher hazard ratio (P<0.05), in analyzed regression models, compared with the carriers of GSTM1-null genotype. Finally, the presence of GSTM1:ASK1 protein-protein interaction was found in all RCC tissue samples studied.RESULTSWe noted an increased risk of RCC development in carriers of GSTM1-null and GSTP1-variant genotype (P<0.05). On the contrary, survival analysis indicated shorter overall survival for patients with ccRCC with GSTM1-active genotype (P = 0.026). Furthermore, patients with ccRCC with GSTM1-active genotype had significantly higher hazard ratio (P<0.05), in analyzed regression models, compared with the carriers of GSTM1-null genotype. Finally, the presence of GSTM1:ASK1 protein-protein interaction was found in all RCC tissue samples studied.Carriers of GSTM1-null and GSTP1-variant genotypes are in increased risk of RCC development. On the contrary, GSTM1-null genotype is associated with favorable postoperative prognosis in ccRCC. The possible molecular mechanism underlying the role of GSTM1 protein in RCC progression might be the presence of GSTM1:ASK1 protein-protein interaction. Hence, determination of GSTM1-genotype might serve as a valuable indicator in both RCC risk assessment and postoperative prognosis.CONCLUSIONSCarriers of GSTM1-null and GSTP1-variant genotypes are in increased risk of RCC development. On the contrary, GSTM1-null genotype is associated with favorable postoperative prognosis in ccRCC. The possible molecular mechanism underlying the role of GSTM1 protein in RCC progression might be the presence of GSTM1:ASK1 protein-protein interaction. Hence, determination of GSTM1-genotype might serve as a valuable indicator in both RCC risk assessment and postoperative prognosis. |
| Author | Radojevic-Skodric, Sanja M. Coric, Vesna M. Pekmezovic, Tatjana D. Suvakov, Sonja R. Simic, Tatjana P. Basta-Jovanovic, Gordana M. Dzamic, Zoran M. Pljesa-Ercegovac, Marija S. Matic, Marija G. Savic-Radojevic, Ana R. Radic, Tanja M. Dragicevic, Dejan P. |
| Author_xml | – sequence: 1 givenname: Vesna M. surname: Coric fullname: Coric, Vesna M. organization: Institute of Medical and Clinical Biochemistry, Belgrade, Serbia – sequence: 2 givenname: Tatjana P. surname: Simic fullname: Simic, Tatjana P. organization: Institute of Medical and Clinical Biochemistry, Belgrade, Serbia – sequence: 3 givenname: Tatjana D. surname: Pekmezovic fullname: Pekmezovic, Tatjana D. organization: Institute of Epidemiology, Belgrade, Serbia – sequence: 4 givenname: Gordana M. surname: Basta-Jovanovic fullname: Basta-Jovanovic, Gordana M. organization: Institute of Pathology, Belgrade, Serbia – sequence: 5 givenname: Ana R. surname: Savic-Radojevic fullname: Savic-Radojevic, Ana R. organization: Institute of Medical and Clinical Biochemistry, Belgrade, Serbia – sequence: 6 givenname: Sanja M. surname: Radojevic-Skodric fullname: Radojevic-Skodric, Sanja M. organization: Institute of Pathology, Belgrade, Serbia – sequence: 7 givenname: Marija G. surname: Matic fullname: Matic, Marija G. organization: Institute of Medical and Clinical Biochemistry, Belgrade, Serbia – sequence: 8 givenname: Sonja R. surname: Suvakov fullname: Suvakov, Sonja R. organization: Institute of Medical and Clinical Biochemistry, Belgrade, Serbia – sequence: 9 givenname: Dejan P. surname: Dragicevic fullname: Dragicevic, Dejan P. organization: Clinic of Urology, Clinical Center of Serbia, Belgrade, Serbia – sequence: 10 givenname: Tanja M. surname: Radic fullname: Radic, Tanja M. organization: Faculty of Medicine, University in Belgrade, Belgrade, Serbia – sequence: 11 givenname: Zoran M. surname: Dzamic fullname: Dzamic, Zoran M. organization: Clinic of Urology, Clinical Center of Serbia, Belgrade, Serbia – sequence: 12 givenname: Marija S. surname: Pljesa-Ercegovac fullname: Pljesa-Ercegovac, Marija S. email: m.pljesa.ercegovac@gmail.com, marijaercegovac@med.bg.ac.rs organization: Institute of Medical and Clinical Biochemistry, Belgrade, Serbia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28284893$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk9rFTEUxYNU7B_9CMos3cw0N5mZZBAVKdoKLV20XYc0c1PynJc8k4zwvr0Z3rOLgrSb5ELOORx-ucfkwAePhLwH2gCF_nTVzDFMwZuGURANZQ2l3StyBFLwmrVDf1BmKmQNLR8OyXFKK0qhlQBvyCGTTLZy4Efk7vzm9gqqB_QhbzdYuVRpXzk_4gbL4XO1ieHBh5Sdqaw2OcTyWpkJdawMTlMV0etpNxodjfNhrd-S11ZPCd_t7xNy9-P77dlFfXl9_vPs22VtWtHm-t4asFSOEkcwdtQWrBUtlzCIjoLsBs3aTloYegTgzPKBU4qih46PFPTIT8jHXW4p-XvGlNXapaWK9hjmpAqMXoJgYijSD3vpfL_GUW2iW-u4Vf9QFEG3E5gYUopoHyVA1YJcrdQeuVqQK8pUQV58n574jMs6u-Bz1G561v1158aC6Y_DqJJx6A2OLqLJagzu2YQvTxLM5LwzevqFW0yrMMfyQYWFSsWgbpalWHYCRIHZ96wEfP5_wAsK_AUPK8lK |
| CitedBy_id | crossref_primary_10_1111_cbdd_13011 crossref_primary_10_4103_jcrt_jcrt_1897_22 crossref_primary_10_1002_biof_1560 crossref_primary_10_1186_s12935_019_0792_3 crossref_primary_10_1186_s12881_018_0620_y crossref_primary_10_1111_bju_15752 crossref_primary_10_1155_2021_6617969 crossref_primary_10_3390_cancers11122038 crossref_primary_10_1016_j_exer_2022_108983 crossref_primary_10_3390_cancers14041068 crossref_primary_10_1177_1535370220906518 crossref_primary_10_3390_ijms19123785 |
| Cites_doi | 10.1089/ars.2012.4640 10.1016/j.juro.2009.11.032 10.1371/journal.pone.0160570 10.1038/nrurol.2009.49 10.1016/j.urolonc.2010.10.001 10.1159/000028396 10.1016/j.tips.2012.09.007 10.1007/s13277-013-1513-5 10.1074/jbc.M506771200 10.1126/science.275.5296.90 10.1074/jbc.M203642200 10.3109/0886022X.2012.708380 10.1016/S0140-6736(15)00046-X 10.1146/annurev.pharmtox.45.120403.095857 10.1093/carcin/bgn153 10.1038/bjc.2013.669 10.1016/S0076-6879(05)01021-9 10.1016/j.bbagen.2012.11.019 10.3390/ijerph13040379 10.1111/j.1365-2559.2010.03733.x 10.1016/j.jbior.2012.09.006 10.1074/jbc.M005561200 10.1038/srep17971 10.1371/journal.pone.0063827 10.1016/j.urolonc.2016.04.005 10.1136/oem.60.10.789 10.1093/annonc/mdu259 |
| ContentType | Journal Article |
| Copyright | 2017 Elsevier Inc. Elsevier Inc. Copyright © 2017 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2017 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2017 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.urolonc.2017.02.005 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1873-2496 |
| EndPage | 417 |
| ExternalDocumentID | 28284893 10_1016_j_urolonc_2017_02_005 S1078143917300662 1_s2_0_S1078143917300662 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Ministry of Education, Science and Technological Development of Republic of Serbia, Serbia |
| GroupedDBID | --- --K --M -RU .1- .FO .~1 0R~ 123 1B1 1P~ 1~. 1~5 29Q 4.4 457 4CK 4G. 53G 5RE 5VS 6PF 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACLOT ACRLP ACRPL ADBBV ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AEVXI AFJKZ AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SDF SDG SEL SES SEW SSH SSZ T5K UDS UHS Z5R ZGI ~G- ~HD AACTN AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AJBFU LCYCR 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c474t-bfc1f08d8ed1cfdaf1ff7438197501859a2458f196e1132f39300e76153d01ad3 |
| ISICitedReferencesCount | 14 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000405997400014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1078-1439 1873-2496 |
| IngestDate | Thu Oct 02 09:52:50 EDT 2025 Wed Feb 19 02:42:01 EST 2025 Sat Nov 29 07:04:36 EST 2025 Tue Nov 18 22:34:18 EST 2025 Fri Feb 23 02:13:27 EST 2024 Tue Feb 25 20:09:47 EST 2025 Tue Oct 14 19:37:11 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Risk Glutathione S-transferase Renal cell carcinoma Survival Polymorphism |
| Language | English |
| License | Copyright © 2017 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c474t-bfc1f08d8ed1cfdaf1ff7438197501859a2458f196e1132f39300e76153d01ad3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 28284893 |
| PQID | 1876817279 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1876817279 pubmed_primary_28284893 crossref_primary_10_1016_j_urolonc_2017_02_005 crossref_citationtrail_10_1016_j_urolonc_2017_02_005 elsevier_sciencedirect_doi_10_1016_j_urolonc_2017_02_005 elsevier_clinicalkeyesjournals_1_s2_0_S1078143917300662 elsevier_clinicalkey_doi_10_1016_j_urolonc_2017_02_005 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-06-01 |
| PublicationDateYYYYMMDD | 2017-06-01 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Urologic oncology |
| PublicationTitleAlternate | Urol Oncol |
| PublicationYear | 2017 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Board, Menon (bib5) 2013; 1830 Buzio, De Palma, Mozzoni, Tondel, Buzio, Franchini (bib21) 2003; 60 Hollman, Tchounwou, Huang (bib6) 2016; 13 Dorion, Lambert, Landry (bib29) 2002; 277 Tew, Townsend (bib10) 2012; 17 Coric, Simic, Pekmezovic, Basta-Jovanovic, Savic Radojevic, Radojevic-Skodric (bib16) 2016; 11 Escudier, Porta, Schmidinger, Algaba, Patard, Khoo (bib1) 2014; 25 Yang, Long, Deng, Deng, Gong, Hao (bib18) 2013; 8 Jia, Liu, Cong, Ma, Sun, Fu (bib19) 2014; 35 Cheng, You, Zhou (bib17) 2012; 34 Ichijo, Nishida, Irie, ten Dijke, Saitoh, Moriguchi (bib25) 1997; 275 Guengerich (bib20) 2005; 401 Huang, Shi, Hou, Mo, Xie (bib13) 2015; 5 Salinas-Sánchez, Sánchez-Sánchez, Donate-Moreno, Rubio-del-Campo, Serrano-Oviedo, Gimenez-Bachs (bib12) 2012; 30 Cho, Lee, Park, Ryoo, Kang, Park (bib28) 2001; 276 Tan, Wang, Han, Chang, Su, Hou (bib3) 2013; 109 Hassan, Feyen, Grinstein (bib30) 2009; 31 Karami, Boffetta, Rothman, Hung, Stewart, Zaridze (bib22) 2008; 29 De Martino, Klatte, Schatzl, Remzi, Waldert, Haitel (bib11) 2010; 183 Hayes, Flanagan, Jowsey (bib8) 2005; 45 Abid, Ajaz, Khan, Zehra, Hasan, Sultan (bib9) 2016 Edge (bib15) 2010 Noguchi, Takeda, Matsuzawa, Saegusa, Nakano, Gohda (bib27) 2005; 280 Hayes, Strange (bib4) 2000; 61 Sobin, Gospodarowicz, Wittekind (bib14) 2010 Shiizaki, Naguro, Ichijo (bib26) 2013; 53 Searchfield, Price, Betton, Jasani, Riccardi, Griffiths (bib24) 2011; 58 Wu, Dong (bib7) 2012; 33 Capitanio, Montorsi (bib2) 2016; 387 Simic, Savic-Radojevic, Pljesa-Ercegovac, Matic, Mimic-Oka (bib23) 2009; 6 Cho (10.1016/j.urolonc.2017.02.005_bib28) 2001; 276 Cheng (10.1016/j.urolonc.2017.02.005_bib17) 2012; 34 Searchfield (10.1016/j.urolonc.2017.02.005_bib24) 2011; 58 Simic (10.1016/j.urolonc.2017.02.005_bib23) 2009; 6 Wu (10.1016/j.urolonc.2017.02.005_bib7) 2012; 33 Coric (10.1016/j.urolonc.2017.02.005_bib16) 2016; 11 Capitanio (10.1016/j.urolonc.2017.02.005_bib2) 2016; 387 Edge (10.1016/j.urolonc.2017.02.005_bib15) 2010 Hassan (10.1016/j.urolonc.2017.02.005_bib30) 2009; 31 Hollman (10.1016/j.urolonc.2017.02.005_bib6) 2016; 13 Tan (10.1016/j.urolonc.2017.02.005_bib3) 2013; 109 Guengerich (10.1016/j.urolonc.2017.02.005_bib20) 2005; 401 Shiizaki (10.1016/j.urolonc.2017.02.005_bib26) 2013; 53 Escudier (10.1016/j.urolonc.2017.02.005_bib1) 2014; 25 Karami (10.1016/j.urolonc.2017.02.005_bib22) 2008; 29 De Martino (10.1016/j.urolonc.2017.02.005_bib11) 2010; 183 Salinas-Sánchez (10.1016/j.urolonc.2017.02.005_bib12) 2012; 30 Noguchi (10.1016/j.urolonc.2017.02.005_bib27) 2005; 280 Yang (10.1016/j.urolonc.2017.02.005_bib18) 2013; 8 Sobin (10.1016/j.urolonc.2017.02.005_bib14) 2010 Huang (10.1016/j.urolonc.2017.02.005_bib13) 2015; 5 Abid (10.1016/j.urolonc.2017.02.005_bib9) 2016 Jia (10.1016/j.urolonc.2017.02.005_bib19) 2014; 35 Hayes (10.1016/j.urolonc.2017.02.005_bib4) 2000; 61 Hayes (10.1016/j.urolonc.2017.02.005_bib8) 2005; 45 Buzio (10.1016/j.urolonc.2017.02.005_bib21) 2003; 60 Board (10.1016/j.urolonc.2017.02.005_bib5) 2013; 1830 Ichijo (10.1016/j.urolonc.2017.02.005_bib25) 1997; 275 Dorion (10.1016/j.urolonc.2017.02.005_bib29) 2002; 277 Tew (10.1016/j.urolonc.2017.02.005_bib10) 2012; 17 |
| References_xml | – volume: 30 start-page: 864 year: 2012 end-page: 870 ident: bib12 article-title: GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer publication-title: Urol Oncol – year: 2010 ident: bib14 article-title: International Union against Cancer, editors publication-title: TNM Classification of Malignant Tumours – volume: 8 start-page: e63827 year: 2013 ident: bib18 article-title: Glutathione S-Transferase polymorphisms (GSTM1, GSTT1 and GSTP1) and their susceptibility to renal cell carcinoma: an evidence-based meta-analysis publication-title: PLoS One – volume: 276 start-page: 12749 year: 2001 end-page: 12755 ident: bib28 article-title: Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1 publication-title: J Biol Chem – volume: 277 start-page: 30792 year: 2002 end-page: 30797 ident: bib29 article-title: Activation of the p38 signaling pathway by heat shock involves the dissociation of glutathione S-transferase Mu from Ask1 publication-title: J Biol Chem – volume: 5 start-page: 17971 year: 2015 ident: bib13 article-title: GSTM1 and GSTT1 polymorphisms contribute to renal cell carcinoma risk: evidence from an updated meta-analysis publication-title: Sci Rep – volume: 53 start-page: 135 year: 2013 end-page: 144 ident: bib26 article-title: Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling publication-title: Adv Biol Regul – volume: 387 start-page: 894 year: 2016 end-page: 906 ident: bib2 article-title: Renal cancer publication-title: The Lancet – volume: 109 start-page: 3105 year: 2013 end-page: 3115 ident: bib3 article-title: Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression publication-title: Br J Cancer – volume: 29 start-page: 1567 year: 2008 end-page: 1571 ident: bib22 article-title: Renal cell carcinoma, occupational pesticide exposure and modification by glutathione S-transferase polymorphisms publication-title: Carcinogenesis – volume: 33 start-page: 656 year: 2012 end-page: 668 ident: bib7 article-title: Human cytosolic glutathione transferases: structure, function, and drug discovery publication-title: Trends Pharmacol Sci – volume: 6 start-page: 281 year: 2009 end-page: 289 ident: bib23 article-title: Glutathione S-transferases in kidney and urinary bladder tumors publication-title: Nat Rev Urol – volume: 31 start-page: 437 year: 2009 end-page: 456 ident: bib30 article-title: Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation publication-title: Cell Oncol Off J Int Soc Cell Oncol – volume: 61 start-page: 154 year: 2000 end-page: 166 ident: bib4 article-title: Glutathione S-transferase polymorphisms and their biological consequences publication-title: Pharmacology – volume: 280 start-page: 37033 year: 2005 end-page: 37040 ident: bib27 article-title: Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death publication-title: J Biol Chem – volume: 17 start-page: 1728 year: 2012 end-page: 1737 ident: bib10 article-title: Glutathione-s-transferases as determinants of cell survival and death publication-title: Antioxid Redox Signal – year: 2016 ident: bib9 article-title: Analysis of the glutathione S-transferase genes polymorphisms in the risk and prognosis of renal cell carcinomas. Case-control and meta-analysis publication-title: Urol Oncol – volume: 58 start-page: 180 year: 2011 end-page: 190 ident: bib24 article-title: Glutathione S-transferases as molecular markers of tumour progression and prognosis in renal cell carcinoma: GST-alpha in human RCC publication-title: Histopathology – volume: 25 start-page: iii49 year: 2014 end-page: iii56 ident: bib1 article-title: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 60 start-page: 789 year: 2003 end-page: 793 ident: bib21 article-title: Glutathione S-transferases M1-1 and T1-1 as risk modifiers for renal cell cancer associated with occupational exposure to chemicals publication-title: Occup Environ Med – volume: 183 start-page: 878 year: 2010 end-page: 883 ident: bib11 article-title: Renal cell carcinoma Fuhrman grade and histological subtype correlate with complete polymorphic deletion of glutathione S-transferase M1 gene publication-title: J Urol – volume: 45 start-page: 51 year: 2005 end-page: 88 ident: bib8 article-title: Glutathione transferases publication-title: Annu Rev Pharmacol Toxicol – volume: 1830 start-page: 3267 year: 2013 end-page: 3288 ident: bib5 article-title: Glutathione transferases, regulators of cellular metabolism and physiology publication-title: Biochim Biophys Acta – volume: 275 start-page: 90 year: 1997 end-page: 94 ident: bib25 article-title: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways publication-title: Science – volume: 13 start-page: 379 year: 2016 ident: bib6 article-title: The association between gene-environment interactions and diseases involving the human GST superfamily with SNP variants publication-title: Int J Environ Res Public Health – volume: 401 start-page: 342 year: 2005 end-page: 353 ident: bib20 article-title: Activation of alkyl halides by glutathione transferases publication-title: Methods Enzymol – volume: 34 start-page: 1052 year: 2012 end-page: 1057 ident: bib17 article-title: Relationship between GSTM1/GSTT1 null genotypes and renal cell carcinoma risk: a meta-analysis publication-title: Ren Fail – volume: 35 start-page: 3867 year: 2014 end-page: 3873 ident: bib19 article-title: Association of glutathione S-transferase M1, T1, and P1 polymorphisms with renal cell carcinoma: evidence from 11 studies publication-title: Tumor Biol – year: 2010 ident: bib15 article-title: American Joint Committee on Cancer publication-title: AJCC Cancer Staging Manual – volume: 11 start-page: e0160570 year: 2016 ident: bib16 article-title: Combined GSTM1-null, GSTT1-active, GSTA1 low-activity and GSTP1-variant genotype is associated with increased risk of clear cell renal cell carcinoma publication-title: PloS One – volume: 17 start-page: 1728 year: 2012 ident: 10.1016/j.urolonc.2017.02.005_bib10 article-title: Glutathione-s-transferases as determinants of cell survival and death publication-title: Antioxid Redox Signal doi: 10.1089/ars.2012.4640 – volume: 183 start-page: 878 year: 2010 ident: 10.1016/j.urolonc.2017.02.005_bib11 article-title: Renal cell carcinoma Fuhrman grade and histological subtype correlate with complete polymorphic deletion of glutathione S-transferase M1 gene publication-title: J Urol doi: 10.1016/j.juro.2009.11.032 – volume: 11 start-page: e0160570 year: 2016 ident: 10.1016/j.urolonc.2017.02.005_bib16 article-title: Combined GSTM1-null, GSTT1-active, GSTA1 low-activity and GSTP1-variant genotype is associated with increased risk of clear cell renal cell carcinoma publication-title: PloS One doi: 10.1371/journal.pone.0160570 – volume: 6 start-page: 281 year: 2009 ident: 10.1016/j.urolonc.2017.02.005_bib23 article-title: Glutathione S-transferases in kidney and urinary bladder tumors publication-title: Nat Rev Urol doi: 10.1038/nrurol.2009.49 – volume: 31 start-page: 437 year: 2009 ident: 10.1016/j.urolonc.2017.02.005_bib30 article-title: Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation publication-title: Cell Oncol Off J Int Soc Cell Oncol – volume: 30 start-page: 864 year: 2012 ident: 10.1016/j.urolonc.2017.02.005_bib12 article-title: GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer publication-title: Urol Oncol doi: 10.1016/j.urolonc.2010.10.001 – volume: 61 start-page: 154 year: 2000 ident: 10.1016/j.urolonc.2017.02.005_bib4 article-title: Glutathione S-transferase polymorphisms and their biological consequences publication-title: Pharmacology doi: 10.1159/000028396 – volume: 33 start-page: 656 year: 2012 ident: 10.1016/j.urolonc.2017.02.005_bib7 article-title: Human cytosolic glutathione transferases: structure, function, and drug discovery publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2012.09.007 – volume: 35 start-page: 3867 year: 2014 ident: 10.1016/j.urolonc.2017.02.005_bib19 article-title: Association of glutathione S-transferase M1, T1, and P1 polymorphisms with renal cell carcinoma: evidence from 11 studies publication-title: Tumor Biol doi: 10.1007/s13277-013-1513-5 – volume: 280 start-page: 37033 year: 2005 ident: 10.1016/j.urolonc.2017.02.005_bib27 article-title: Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death publication-title: J Biol Chem doi: 10.1074/jbc.M506771200 – volume: 275 start-page: 90 year: 1997 ident: 10.1016/j.urolonc.2017.02.005_bib25 article-title: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways publication-title: Science doi: 10.1126/science.275.5296.90 – volume: 277 start-page: 30792 year: 2002 ident: 10.1016/j.urolonc.2017.02.005_bib29 article-title: Activation of the p38 signaling pathway by heat shock involves the dissociation of glutathione S-transferase Mu from Ask1 publication-title: J Biol Chem doi: 10.1074/jbc.M203642200 – volume: 34 start-page: 1052 year: 2012 ident: 10.1016/j.urolonc.2017.02.005_bib17 article-title: Relationship between GSTM1/GSTT1 null genotypes and renal cell carcinoma risk: a meta-analysis publication-title: Ren Fail doi: 10.3109/0886022X.2012.708380 – volume: 387 start-page: 894 year: 2016 ident: 10.1016/j.urolonc.2017.02.005_bib2 article-title: Renal cancer publication-title: The Lancet doi: 10.1016/S0140-6736(15)00046-X – volume: 45 start-page: 51 year: 2005 ident: 10.1016/j.urolonc.2017.02.005_bib8 article-title: Glutathione transferases publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev.pharmtox.45.120403.095857 – year: 2010 ident: 10.1016/j.urolonc.2017.02.005_bib14 article-title: International Union against Cancer, editors – volume: 29 start-page: 1567 year: 2008 ident: 10.1016/j.urolonc.2017.02.005_bib22 article-title: Renal cell carcinoma, occupational pesticide exposure and modification by glutathione S-transferase polymorphisms publication-title: Carcinogenesis doi: 10.1093/carcin/bgn153 – volume: 109 start-page: 3105 year: 2013 ident: 10.1016/j.urolonc.2017.02.005_bib3 article-title: Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression publication-title: Br J Cancer doi: 10.1038/bjc.2013.669 – volume: 401 start-page: 342 year: 2005 ident: 10.1016/j.urolonc.2017.02.005_bib20 article-title: Activation of alkyl halides by glutathione transferases publication-title: Methods Enzymol doi: 10.1016/S0076-6879(05)01021-9 – volume: 1830 start-page: 3267 year: 2013 ident: 10.1016/j.urolonc.2017.02.005_bib5 article-title: Glutathione transferases, regulators of cellular metabolism and physiology publication-title: Biochim Biophys Acta doi: 10.1016/j.bbagen.2012.11.019 – volume: 13 start-page: 379 year: 2016 ident: 10.1016/j.urolonc.2017.02.005_bib6 article-title: The association between gene-environment interactions and diseases involving the human GST superfamily with SNP variants publication-title: Int J Environ Res Public Health doi: 10.3390/ijerph13040379 – volume: 58 start-page: 180 year: 2011 ident: 10.1016/j.urolonc.2017.02.005_bib24 article-title: Glutathione S-transferases as molecular markers of tumour progression and prognosis in renal cell carcinoma: GST-alpha in human RCC publication-title: Histopathology doi: 10.1111/j.1365-2559.2010.03733.x – volume: 53 start-page: 135 year: 2013 ident: 10.1016/j.urolonc.2017.02.005_bib26 article-title: Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling publication-title: Adv Biol Regul doi: 10.1016/j.jbior.2012.09.006 – volume: 276 start-page: 12749 year: 2001 ident: 10.1016/j.urolonc.2017.02.005_bib28 article-title: Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1 publication-title: J Biol Chem doi: 10.1074/jbc.M005561200 – volume: 5 start-page: 17971 year: 2015 ident: 10.1016/j.urolonc.2017.02.005_bib13 article-title: GSTM1 and GSTT1 polymorphisms contribute to renal cell carcinoma risk: evidence from an updated meta-analysis publication-title: Sci Rep doi: 10.1038/srep17971 – volume: 8 start-page: e63827 year: 2013 ident: 10.1016/j.urolonc.2017.02.005_bib18 article-title: Glutathione S-Transferase polymorphisms (GSTM1, GSTT1 and GSTP1) and their susceptibility to renal cell carcinoma: an evidence-based meta-analysis publication-title: PLoS One doi: 10.1371/journal.pone.0063827 – year: 2016 ident: 10.1016/j.urolonc.2017.02.005_bib9 article-title: Analysis of the glutathione S-transferase genes polymorphisms in the risk and prognosis of renal cell carcinomas. Case-control and meta-analysis publication-title: Urol Oncol doi: 10.1016/j.urolonc.2016.04.005 – volume: 60 start-page: 789 year: 2003 ident: 10.1016/j.urolonc.2017.02.005_bib21 article-title: Glutathione S-transferases M1-1 and T1-1 as risk modifiers for renal cell cancer associated with occupational exposure to chemicals publication-title: Occup Environ Med doi: 10.1136/oem.60.10.789 – year: 2010 ident: 10.1016/j.urolonc.2017.02.005_bib15 article-title: American Joint Committee on Cancer – volume: 25 start-page: iii49 year: 2014 ident: 10.1016/j.urolonc.2017.02.005_bib1 article-title: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdu259 |
| SSID | ssj0014811 |
| Score | 2.2119386 |
| Snippet | Owing to dual functionality of cytosolic glutathione S-transferases (GSTs), they might affect both the development and the progression of renal cell carcinoma... Abstract Purpose Owing to dual functionality of cytosolic glutathione S-transferases (GSTs), they might affect both the development and the progression of... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 409 |
| SubjectTerms | Carcinoma, Renal Cell - enzymology Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - pathology Case-Control Studies Female Genetic Predisposition to Disease Genotype Glutathione S-transferase Glutathione Transferase - genetics Humans Kidney Neoplasms - enzymology Kidney Neoplasms - genetics Kidney Neoplasms - pathology Male Middle Aged Polymorphism Prognosis Renal cell carcinoma Retrospective Studies Risk Survival Urology |
| Title | GSTM1 genotype is an independent prognostic factor in clear cell renal cell carcinoma |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1078143917300662 https://www.clinicalkey.es/playcontent/1-s2.0-S1078143917300662 https://dx.doi.org/10.1016/j.urolonc.2017.02.005 https://www.ncbi.nlm.nih.gov/pubmed/28284893 https://www.proquest.com/docview/1876817279 |
| Volume | 35 |
| WOSCitedRecordID | wos000405997400014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect database customDbUrl: eissn: 1873-2496 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014811 issn: 1078-1439 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9swEBdpO8Zexr6XfRQPxl6CO8sfkfzYlbRbSbNCHcibkGUZkrV2Fieh7J_Yv7w7W7ZTltLuYS9GyJZldD-d7s7S7wj5mMRxEHiK28qVqe2nyrN5n2nb82UcgjIEC7tk1x-y0YhPJuF5p_O7PguzvmRZxq-vw_l_FTXUgbDx6Ow_iLt5KVRAGYQOVxA7XO8l-JOL6IxiZuS8DK9OkYS5N22y3S7LLVlZjvzMJtsOxjwUpo_oYRi_t9BooZZFhZmGstzobmPDjheVwuzlmboRlD9CvpFy46wuMrmRqXh6VdVHcjmTcOe8Vcg_rvSvfH3zdrMJ-YsE29U-zcHar585AWdZNi834QrK2m1VRsNy5tng8xn-6y11Ri1XLCYGfps61i_5FP7W_VUYYnawwlHIkJ6SsoqPNWgXu_oH_-i7OB4PhyIaTKJP8582piHD3_UmJ8sO2XNZEIKa3Dv8NpicNj-mfF6mdG6-uD0U9nlrz7eZO7e5M6VZEz0hj40_Yh1WOHpKOjp7Rh6emR0Xz8m4hJNVw8maFpbMrA04WS2crApOcNcq4WQhhqwSTlWxgdMLMj4eREdfbZOKw1Y-85d2nCqaOjzhOqEqTWRK05QhO1zIkBEyCKXrBzyFqa0p9dzUCz3H0Qy9icShMvFekt0sz_RrYsXU7YfK92GlZb6isVQpAyeFh4njpr70usSvR0wow1OP6VIuRb0hcSbMQAscaOG4Aga6Sw6aZvOKqOWuBv1aHKI-hQzrpgA43dWQbWuoC6MECkFFAU-KC4pMWni0HZNC9Ptul_CmpTFwK8P1Pp1-qBEjYAFAoclM5yvoDOwZjm5I2CWvKig1A4DxFGSXenOP1m_Jo3a-viO7y8VKvycP1Ho5LRb7ZIdN-L6ZDX8A0ajcpA |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=GSTM1+genotype+is+an+independent+prognostic+factor+in+clear+cell+renal+cell+carcinoma&rft.jtitle=Urologic+oncology&rft.au=Coric%2C+Vesna+M&rft.au=Simic%2C+Tatjana+P&rft.au=Pekmezovic%2C+Tatjana+D&rft.au=Basta-Jovanovic%2C+Gordana+M&rft.date=2017-06-01&rft.issn=1873-2496&rft.eissn=1873-2496&rft.volume=35&rft.issue=6&rft.spage=409&rft_id=info:doi/10.1016%2Fj.urolonc.2017.02.005&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10781439%2FS1078143916X0018X%2Fcov150h.gif |